|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM371523435 |
| 003 |
DE-627 |
| 005 |
20240822232627.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240426s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2024.110228
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1509.xml
|
| 035 |
|
|
|a (DE-627)NLM371523435
|
| 035 |
|
|
|a (NLM)38663494
|
| 035 |
|
|
|a (PII)S1521-6616(24)00119-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Xu, Liping
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Eosinophil peroxidase promotes bronchial epithelial cells to secrete asthma-related factors and induces the early stage of airway remodeling
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.05.2024
|
| 500 |
|
|
|a Date Revised 21.08.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Asthma is a heterogeneous disease characterized by chronic airway inflammation, reversible airflow limitation, and airway remodeling. Eosinophil peroxidase (EPX) is the most abundant secondary granule protein unique to activated eosinophils. In this study, we aimed to illustrate the effect of EPX on the epithelial-mesenchymal transition (EMT) in BEAS-2B cells. Our research found that both EPX and ADAM33 were negatively correlated with FEV1/FVC and FEV1%pred, and positively correlated with IL-5 levels. Asthma patients had relatively higher levels of ADAM33 and EPX compared to the healthy control group. The expression of TSLP, TGF-β1 and ADAM33 in the EPX intervention group was significantly higher. Moreover, EPX could promote the proliferation, migration and EMT of BEAS-2B cells, and the effect of EPX on various factors was significantly improved by the PI3K inhibitor LY294002. The findings from this study could potentially offer a novel therapeutic target for addressing airway remodeling in bronchial asthma, particularly focusing on EMT
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Airway remodeling
|
| 650 |
|
4 |
|a Asthma
|
| 650 |
|
4 |
|a Eosinophil peroxidase
|
| 650 |
|
4 |
|a Epithelial-mesenchymal transition
|
| 650 |
|
4 |
|a Inflammatory
|
| 650 |
|
7 |
|a ADAM33 protein, human
|2 NLM
|
| 650 |
|
7 |
|a TSLP protein, human
|2 NLM
|
| 650 |
|
7 |
|a 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
|2 NLM
|
| 650 |
|
7 |
|a IL5 protein, human
|2 NLM
|
| 650 |
|
7 |
|a TGFB1 protein, human
|2 NLM
|
| 700 |
1 |
|
|a Huang, Xuemei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Zhangrong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Meiling
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Deng, Jingmin
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 263(2024) vom: 22. Juni, Seite 110228
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:263
|g year:2024
|g day:22
|g month:06
|g pages:110228
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2024.110228
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 263
|j 2024
|b 22
|c 06
|h 110228
|